New pill aims to slow vision loss in dry AMD
NCT ID NCT05170048
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental pill (EG-301) taken daily for at least 6 months in 90 people with dry age-related macular degeneration (AMD) and geographic atrophy. Participants are randomly assigned to receive either standard AREDS2 supplements alone or AREDS2 plus EG-301. The goal is to see if EG-301 can safely slow vision loss and reduce damage to the retina.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-EXUDATIVE (DRY) AGE-RELATED MACULAR DEGENERATION (DAMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••